Categories
Change Password!
Reset Password!
A study compared the efficacy of Telmisartan with Perindopril in treating older individuals with ischemic stroke, arterial hypertension, and metabolic syndrome.
Twelve months of 80 mg/day Telmisartan pharmacotherapy effectively reduces systolic and diastolic blood pressure values in elderly hypertension patients with metabolic syndrome and ischemic stroke history.
A study compared the efficacy of Telmisartan with Perindopril in treating older individuals with ischemic stroke, arterial hypertension, and metabolic syndrome.
Overall, 92 senior volunteers (mean age 68±4 years) who experienced an ischemic stroke and had metabolic syndrome and arterial hypertension were investigated. Participants were randomly assigned to one of two medication groups; 45 subjects received Perindopril (10 mg/day), whereas 47 subjects received Telmisartan (80 mg/day).
The Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) index was estimated, the high- and low-density lipoprotein cholesterol, triglycerides, total cholesterol, leptin, insulin, and fasting plasma glucose levels were all determined and daily monitoring was done. STATISTICA 10.0 was used to process the statistical data. The indicators were shown as the mean ± Standard Deviation, Me (Q25%; Q75%) interquartile ranges, and median. The Wilcoxon rank criteria was used to compare the two groups. At p<0.05, the differences were considerable.
In the Telmisartan group, there was a substantial reduction in average daily systolic blood pressure from 152 (146; 156) to 129 (125; 134) mm Hg and diastolic blood pressure from 89 (83; 96) to 76 (72; 84) mm Hg, as well as a decrease in HOMA-IR from 4,1 (3,3; 5,0) to 3,2 (2,7; 3,6) units, leptin from 14,3 (10,2; 17,7) to 11,7 (10,8; 13,6) ng/ml, triglycerides from 2,25 (1,90; 2,53) up to 2,05 (1,84; 2,05) mmol/l. In the Perindopril group, systolic blood pressure decreased from 149 (144; 154) to 137 (131; 142) mm Hg, and leptin decreased from 14,4 (10,3; 18,0) to 13,0 (12,3; 13,8) ng/ml. Reduction in НOMА-IR and triglycerides was also noted.
After receiving Telmisartan for a year, older individuals with hypertension, metabolic syndrome, and ischemic stroke history had significantly lower systolic and diastolic blood pressure values, reduced insulin resistance, and minimized levels of leptin and triglycerides in their blood serum.
Cardiovascular Therapy and Prevention
Advantages of Telmisartan pharmacotherapy in elderly patients with arterial hypertension and metabolic syndrome who have suffered an ischemic stroke
O. A. Osipova et al.
Comments (0)